{"pmid":32448039,"title":"In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2.","text":["In-silico strategies for probing chloroquine based inhibitors against SARS-CoV-2.","The global health emergency of novel COVID-19 is due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Currently there are no approved drugs for the treatment of coronaviral disease (COVID-19), although some of the drugs have been tried. Chloroquine is being widely used in treatment of SARS-CoV-2 infection. Hydroxychloroquine, the derivative of Chloroquine shows better inhibition than Chloroquine and has in vitro activity against SARS-CoV-2 also used to treat COVID-19. To study the interactions of Chloroquine and derivatives of Chloroquine with SARS-CoV-2, series of computational approaches like pharmacophore model, molecular docking, MM_GBSA study and ADME property analysis are explored. The pharmacophore model and molecular docking study are used to explore the structural properties of the compounds and the ligand-receptor (PDB_ID: 6LU7) interactions respectively. MM_GBSA study gives the binding free energy of the protein-ligand complex and ADME property analysis explains the pharmacological property of the compounds. The resultant best molecule (CQD15) further subjected to molecular dynamics (MD) simulation study which explains the protein stability (RMSD), ligand properties as well as protein-ligand contacts. Outcomes of the present study conclude with the molecule CQD15 which shows better interactions for the inhibition of SARS-CoV-2 in comparison to Chloroquine and Hydroxychloroquine.","J Biomol Struct Dyn","Beura, Satyajit","Prabhakar, Chetti","32448039"],"abstract":["The global health emergency of novel COVID-19 is due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Currently there are no approved drugs for the treatment of coronaviral disease (COVID-19), although some of the drugs have been tried. Chloroquine is being widely used in treatment of SARS-CoV-2 infection. Hydroxychloroquine, the derivative of Chloroquine shows better inhibition than Chloroquine and has in vitro activity against SARS-CoV-2 also used to treat COVID-19. To study the interactions of Chloroquine and derivatives of Chloroquine with SARS-CoV-2, series of computational approaches like pharmacophore model, molecular docking, MM_GBSA study and ADME property analysis are explored. The pharmacophore model and molecular docking study are used to explore the structural properties of the compounds and the ligand-receptor (PDB_ID: 6LU7) interactions respectively. MM_GBSA study gives the binding free energy of the protein-ligand complex and ADME property analysis explains the pharmacological property of the compounds. The resultant best molecule (CQD15) further subjected to molecular dynamics (MD) simulation study which explains the protein stability (RMSD), ligand properties as well as protein-ligand contacts. Outcomes of the present study conclude with the molecule CQD15 which shows better interactions for the inhibition of SARS-CoV-2 in comparison to Chloroquine and Hydroxychloroquine."],"journal":"J Biomol Struct Dyn","authors":["Beura, Satyajit","Prabhakar, Chetti"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448039","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1080/07391102.2020.1772111","keywords":["covid-19","molecular docking","molecular dynamics simulations","pharmacophore model","sars-cov-2"],"e_drugs":["Hydroxychloroquine","Chloroquine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667785213902585857,"score":9.490897,"similar":[{"pmid":32329419,"title":"Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach.","text":["Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach.","SARS-CoV-2 virus which caused the global pandemic the Coronavirus Disease- 2019 (COVID-2019) has infected about 1,203,959 patients and brought forth death rate about 64,788 among 206 countries as mentioned by WHO in the month of April 2020. The clinical trials are underway for Remdesivir, an investigational anti-viral drug from Gilead Sciences. Antimalarial drugs such as Chloroquine and Hydroxychloroquine derivatives are being used in emergency cases; however, they are not suitable for patients with conditions like diabetes, hypertension and cardiac issues. The lack of availability of approved treatment for this disease calls forth the scientific community to find novel compounds with the ability to treat it. This paper evaluates the compound Andrographolide from Andrographis paniculata as a potential inhibitor of the main protease of SARS-COV-2 (Mpro) through in silico studies such as molecular docking, target analysis, toxicity prediction and ADME prediction. Andrographolide was docked successfully in the binding site of SARS-CoV-2 Mpro. Computational approaches also predicts this molecule to have good solubility, pharmacodynamics property and target accuracy. This molecule also obeys Lipinski's rule, which makes it a promising compound to pursue further biochemical and cell based assays to explore its potential for use against COVID-19.Communicated by Ramaswamy H. Sarma.","J Biomol Struct Dyn","Enmozhi, Sukanth Kumar","Raja, Kavitha","Sebastine, Irudhayasamy","Joseph, Jerrine","32329419"],"abstract":["SARS-CoV-2 virus which caused the global pandemic the Coronavirus Disease- 2019 (COVID-2019) has infected about 1,203,959 patients and brought forth death rate about 64,788 among 206 countries as mentioned by WHO in the month of April 2020. The clinical trials are underway for Remdesivir, an investigational anti-viral drug from Gilead Sciences. Antimalarial drugs such as Chloroquine and Hydroxychloroquine derivatives are being used in emergency cases; however, they are not suitable for patients with conditions like diabetes, hypertension and cardiac issues. The lack of availability of approved treatment for this disease calls forth the scientific community to find novel compounds with the ability to treat it. This paper evaluates the compound Andrographolide from Andrographis paniculata as a potential inhibitor of the main protease of SARS-COV-2 (Mpro) through in silico studies such as molecular docking, target analysis, toxicity prediction and ADME prediction. Andrographolide was docked successfully in the binding site of SARS-CoV-2 Mpro. Computational approaches also predicts this molecule to have good solubility, pharmacodynamics property and target accuracy. This molecule also obeys Lipinski's rule, which makes it a promising compound to pursue further biochemical and cell based assays to explore its potential for use against COVID-19.Communicated by Ramaswamy H. Sarma."],"journal":"J Biomol Struct Dyn","authors":["Enmozhi, Sukanth Kumar","Raja, Kavitha","Sebastine, Irudhayasamy","Joseph, Jerrine"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329419","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1080/07391102.2020.1760136","keywords":["andrographolide","sars-cov-2","swiss-bioinformatics","in silico studies","plant compound"],"locations":["Andrographis"],"e_drugs":["remdesivir","Chloroquine","Hydroxychloroquine","andrographolide"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494594973696,"score":431.09305},{"pmid":32362217,"title":"In silico study the inhibition of Angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from western Algeria.","text":["In silico study the inhibition of Angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from western Algeria.","The objective of this present study is to focus on the in silico study to screen for an alternative drug that can block the activity of the angiotensin converting enzyme 2 (ACE2) as a receptor for SARS-CoV-2, potential therapeutic target of the COVID-19 virus using natural compounds (Isothymol, Thymol, Limonene, P-cymene and gamma-terpinene) derived from the essential oil of the antiviral and antimicrobial plant Ammoides verticillata (Desf.) Briq. which is located in the occidental Algeria areas. This study reveals that Isothymol, a major component of this plant, gives the best docking scores, compared to, the co-crystallized inhibitor beta-D-mannose of the enzyme ACE2, to Captropil drug as good ACE2 inhibitor and to Chloroquine antiviral drug also involved in other mechanisms as inhibition of ACE2 cellular receptor. In silico (ADME), drug-likeness, PASS & P450 site of metabolism prediction, pharmacophore Mapper showed that the compound Isothymol has give a good tests results compared to the beta-D-mannose co-crystallized inhibitor, to Captopril and Chloroquine drugs. Also the other natural compounds gave good results. The Molecular Dynamics Simulation study showed good result for the Isotymol- ACE2 docked complex. This study revealed for the first time that Isothymol is a functional inhibitor of angiotensin converting enzyme 2 activity and the components of essential oils Ammoides verticillata can be used as a potential inhibitors to the ACE2 receptor of SARS-CoV-2.","J Biomol Struct Dyn","Abdelli, Imane","Hassani, Faical","Bekkel Brikci, Sohayb","Ghalem, Said","32362217"],"abstract":["The objective of this present study is to focus on the in silico study to screen for an alternative drug that can block the activity of the angiotensin converting enzyme 2 (ACE2) as a receptor for SARS-CoV-2, potential therapeutic target of the COVID-19 virus using natural compounds (Isothymol, Thymol, Limonene, P-cymene and gamma-terpinene) derived from the essential oil of the antiviral and antimicrobial plant Ammoides verticillata (Desf.) Briq. which is located in the occidental Algeria areas. This study reveals that Isothymol, a major component of this plant, gives the best docking scores, compared to, the co-crystallized inhibitor beta-D-mannose of the enzyme ACE2, to Captropil drug as good ACE2 inhibitor and to Chloroquine antiviral drug also involved in other mechanisms as inhibition of ACE2 cellular receptor. In silico (ADME), drug-likeness, PASS & P450 site of metabolism prediction, pharmacophore Mapper showed that the compound Isothymol has give a good tests results compared to the beta-D-mannose co-crystallized inhibitor, to Captopril and Chloroquine drugs. Also the other natural compounds gave good results. The Molecular Dynamics Simulation study showed good result for the Isotymol- ACE2 docked complex. This study revealed for the first time that Isothymol is a functional inhibitor of angiotensin converting enzyme 2 activity and the components of essential oils Ammoides verticillata can be used as a potential inhibitors to the ACE2 receptor of SARS-CoV-2."],"journal":"J Biomol Struct Dyn","authors":["Abdelli, Imane","Hassani, Faical","Bekkel Brikci, Sohayb","Ghalem, Said"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32362217","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/07391102.2020.1763199","keywords":["ammoides verticillata","angiotensin converting enzyme 2","covid-19","isothymol","molcular docking"],"locations":["Limonene","Algeria","Algeria"],"countries":["Algeria"],"countries_codes":["DZA|Algeria"],"e_drugs":["4-cymene","gamma-terpinene","carvacrol","Chloroquine","Thymol","Captopril","Oils, Volatile","Limonene"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496047251458,"score":404.76382},{"pmid":32470577,"title":"High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.","text":["High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment.","The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico techniques like receptor-ligand docking, Molecular dynamic (MD), and ADME properties to screen natural compounds. It has been documented that many natural compounds display antiviral activities, including anti-SARS-CoV effect. The present study deals with compounds of Natural Product Activity and Species Source (NPASS) database with known biological activity that probably impedes the activity of six essential enzymes of the virus. Promising drug-like compounds were identified, demonstrating better docking score and binding energy for each druggable targets. After an extensive screening analysis, three novel multi-target natural compounds were predicted to subdue the activity of three/more major drug targets simultaneously. Concerning the utility of natural compounds in the formulation of many therapies, we propose these compounds as excellent lead candidates for the development of therapeutic drugs against SARS-CoV-2.","Int J Biol Macromol","Naik, Biswajit","Gupta, Nidhi","Ojha, Rupal","Singh, Satyendra","Prajapati, Vijay Kumar","Prusty, Dhaneswar","32470577"],"abstract":["The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico techniques like receptor-ligand docking, Molecular dynamic (MD), and ADME properties to screen natural compounds. It has been documented that many natural compounds display antiviral activities, including anti-SARS-CoV effect. The present study deals with compounds of Natural Product Activity and Species Source (NPASS) database with known biological activity that probably impedes the activity of six essential enzymes of the virus. Promising drug-like compounds were identified, demonstrating better docking score and binding energy for each druggable targets. After an extensive screening analysis, three novel multi-target natural compounds were predicted to subdue the activity of three/more major drug targets simultaneously. Concerning the utility of natural compounds in the formulation of many therapies, we propose these compounds as excellent lead candidates for the development of therapeutic drugs against SARS-CoV-2."],"journal":"Int J Biol Macromol","authors":["Naik, Biswajit","Gupta, Nidhi","Ojha, Rupal","Singh, Satyendra","Prajapati, Vijay Kumar","Prusty, Dhaneswar"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470577","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.ijbiomac.2020.05.184","keywords":["covid-19","molecular docking","molecular dynamics","muti-target","natural compounds"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668167110044418048,"score":396.53287},{"pmid":32485652,"pmcid":"PMC7253975","title":"Interaction of the prototypical alpha-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex.","text":["Interaction of the prototypical alpha-ketoamide inhibitor with the SARS-CoV-2 main protease active site in silico: Molecular dynamic simulations highlight the stability of the ligand-protein complex.","The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes an illness known as COVID-19, which has been declared a global pandemic with over 2 million confirmed cases and 137,000 deaths in 185 countries and regions at the time of writing (16 April 2020), over a quarter of these cases being in the United States. In the absence of a vaccine, or an approved effective therapeutic, there is an intense interest in repositioning available drugs or designing small molecule antivirals. In this context, in silico modelling has proven to be an invaluable tool. An important target is the SARS-CoV-2 main protease (M(pro)), involved in processing translated viral proteins. Peptidomimetic alpha-ketoamides represent prototypical inhibitors of M(pro). A recent attempt at designing a compound with enhanced pharmacokinetic properties has resulted in the synthesis and evaluation of the alpha-ketoamide 13b analogue. Here, we performed molecular docking and molecular dynamics simulations to further characterize the interaction of alpha-ketoamide 13b with the active site of the SARS-CoV-2 M(pro). We included the widely used antibiotic, amoxicillin, for comparison. Our findings indicate that alpha-ketoamide 13b binds more tightly (predicted GlideScore = -8.7 and -9.2kcal/mol for protomers A and B, respectively), to the protease active site compared to amoxicillin (-5.0 and -4.8kcal/mol). Further, molecular dynamics simulations highlight the stability of the interaction of the alpha-ketoamide 13b ligand with the SARS-CoV-2 M(pro) (DeltaG = -25.2 and -22.3kcal/mol for protomers A and B). In contrast, amoxicillin interacts unfavourably with the protease (DeltaG = +32.8kcal/mol for protomer A), with unbinding events observed in several independent simulations. Overall, our findings are consistent with those previously observed, and highlight the need to further explore the alpha-ketoamides as potential antivirals for this ongoing COVID-19 pandemic.","Comput Biol Chem","Liang, Julia","Pitsillou, Eleni","Karagiannis, Chris","Darmawan, Kevion K","Ng, Ken","Hung, Andrew","Karagiannis, Tom C","32485652"],"abstract":["The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes an illness known as COVID-19, which has been declared a global pandemic with over 2 million confirmed cases and 137,000 deaths in 185 countries and regions at the time of writing (16 April 2020), over a quarter of these cases being in the United States. In the absence of a vaccine, or an approved effective therapeutic, there is an intense interest in repositioning available drugs or designing small molecule antivirals. In this context, in silico modelling has proven to be an invaluable tool. An important target is the SARS-CoV-2 main protease (M(pro)), involved in processing translated viral proteins. Peptidomimetic alpha-ketoamides represent prototypical inhibitors of M(pro). A recent attempt at designing a compound with enhanced pharmacokinetic properties has resulted in the synthesis and evaluation of the alpha-ketoamide 13b analogue. Here, we performed molecular docking and molecular dynamics simulations to further characterize the interaction of alpha-ketoamide 13b with the active site of the SARS-CoV-2 M(pro). We included the widely used antibiotic, amoxicillin, for comparison. Our findings indicate that alpha-ketoamide 13b binds more tightly (predicted GlideScore = -8.7 and -9.2kcal/mol for protomers A and B, respectively), to the protease active site compared to amoxicillin (-5.0 and -4.8kcal/mol). Further, molecular dynamics simulations highlight the stability of the interaction of the alpha-ketoamide 13b ligand with the SARS-CoV-2 M(pro) (DeltaG = -25.2 and -22.3kcal/mol for protomers A and B). In contrast, amoxicillin interacts unfavourably with the protease (DeltaG = +32.8kcal/mol for protomer A), with unbinding events observed in several independent simulations. Overall, our findings are consistent with those previously observed, and highlight the need to further explore the alpha-ketoamides as potential antivirals for this ongoing COVID-19 pandemic."],"journal":"Comput Biol Chem","authors":["Liang, Julia","Pitsillou, Eleni","Karagiannis, Chris","Darmawan, Kevion K","Ng, Ken","Hung, Andrew","Karagiannis, Tom C"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32485652","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.compbiolchem.2020.107292","keywords":["covid-19","coronavirus","sars-cov-2","sars-cov-2 main protease","molecular docking","molecular dynamics simulations","alpha-ketoamide"],"locations":["United States","amoxicillin"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Amoxicillin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668704334437679104,"score":386.19818},{"pmid":32408547,"title":"Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).","text":["Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused about 2 million infections and is responsible for more than 100,000 deaths worldwide. To date, there is no specific drug registered to combat the disease it causes, named coronavirus disease 2019 (COVID-19). In the current study, we used an in silico approach to screen natural compounds to find potent inhibitors of the host enzyme transmembrane protease serine 2 (TMPRSS2). This enzyme facilitates viral particle entry into host cells, and its inhibition blocks virus fusion with angiotensin-converting enzyme 2 (ACE2). This, in turn, restricts SARS-CoV-2 pathogenesis. A three-dimensional structure of TMPRSS2 was built using SWISS-MODEL and validated by RAMPAGE. The natural compounds library Natural Product Activity and Species Source (NPASS), containing 30,927 compounds, was screened against the target protein. Two techniques were used in the Molecular Operating Environment (MOE) for this purpose, i.e., a ligand-based pharmacophore approach and a molecular docking-based screening. In total, 2140 compounds with pharmacophoric features were retained using the first approach. Using the second approach, 85 compounds with molecular docking comparable to or greater than that of the standard inhibitor (camostat mesylate) were identified. The top 12 compounds with the most favorable structural features were studied for physicochemical and ADMET (absorption, distribution, metabolism, excretion, toxicity) properties. The low-molecular-weight compound NPC306344 showed significant interaction with the active site residues of TMPRSS2, with a binding energy score of -14.69. Further in vitro and in vivo validation is needed to study and develop an anti-COVID-19 drug based on the structures of the most promising compounds identified in this study.","Molecules","Rahman, Noor","Basharat, Zarrin","Yousuf, Muhammad","Castaldo, Giuseppe","Rastrelli, Luca","Khan, Haroon","32408547"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused about 2 million infections and is responsible for more than 100,000 deaths worldwide. To date, there is no specific drug registered to combat the disease it causes, named coronavirus disease 2019 (COVID-19). In the current study, we used an in silico approach to screen natural compounds to find potent inhibitors of the host enzyme transmembrane protease serine 2 (TMPRSS2). This enzyme facilitates viral particle entry into host cells, and its inhibition blocks virus fusion with angiotensin-converting enzyme 2 (ACE2). This, in turn, restricts SARS-CoV-2 pathogenesis. A three-dimensional structure of TMPRSS2 was built using SWISS-MODEL and validated by RAMPAGE. The natural compounds library Natural Product Activity and Species Source (NPASS), containing 30,927 compounds, was screened against the target protein. Two techniques were used in the Molecular Operating Environment (MOE) for this purpose, i.e., a ligand-based pharmacophore approach and a molecular docking-based screening. In total, 2140 compounds with pharmacophoric features were retained using the first approach. Using the second approach, 85 compounds with molecular docking comparable to or greater than that of the standard inhibitor (camostat mesylate) were identified. The top 12 compounds with the most favorable structural features were studied for physicochemical and ADMET (absorption, distribution, metabolism, excretion, toxicity) properties. The low-molecular-weight compound NPC306344 showed significant interaction with the active site residues of TMPRSS2, with a binding energy score of -14.69. Further in vitro and in vivo validation is needed to study and develop an anti-COVID-19 drug based on the structures of the most promising compounds identified in this study."],"journal":"Molecules","authors":["Rahman, Noor","Basharat, Zarrin","Yousuf, Muhammad","Castaldo, Giuseppe","Rastrelli, Luca","Khan, Haroon"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32408547","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/molecules25102271","keywords":["coronavirus","docking","drug design","natural product","serine protease"],"e_drugs":["Serine","camostat"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666897319103037440,"score":379.52206}]}